Back to News
quantum-computing

Viewbix Completes Acquisition of Quantum X Labs, Pivots to Quantum Technology

Quantum Computing Report
Loading...
2 min read
0 likes
⚡ Quantum Brief
Viewbix Inc. (Nasdaq: VBIX) completed its acquisition of Israeli quantum hub QuantumX Labs on March 4, 2026, marking a strategic shift from ad-tech to quantum computing and hardware. The deal grants Viewbix key quantum technologies, including "unjammable" quantum gyroscopes for GPS-denied navigation, AI-driven error correction, and quantum algorithms for drug discovery and logistics. Viewbix issued stock and warrants totaling 40% of its capital, with potential for 12.7 million more shares tied to performance milestones, while raising $1.4 million to fund quantum IP commercialization. This acquisition serves as a reverse-merger entry for Israel’s quantum ecosystem into Nasdaq, leveraging academic ties to Tel Aviv University and the Weizmann Institute. The company’s valuation now hinges on operationalizing QuantumX Labs’ innovations, led by Prof. Nir Sharon, in high-precision sensing and error-correction markets.
Viewbix Completes Acquisition of Quantum X Labs, Pivots to Quantum Technology

Summarize this article with:

Viewbix Completes Acquisition of Quantum X Labs, Pivots to Quantum Technology Viewbix Inc. (Nasdaq: VBIX) has officially finalized its acquisition of QuantumX Labs Ltd., a multidisciplinary Israeli quantum technology hub. The deal, completed on March 4, 2026, represents a significant strategic pivot for Viewbix—originally an ad-tech firm—into the quantum hardware and software sectors. The acquisition includes a specialized intellectual property portfolio and several portfolio companies focused on quantum-based navigation, precision timing (atomic clocks), and AI-driven quantum error correction. Through this acquisition, Viewbix gains control over several distinct technical verticals: Quantum Navigation: Development of “unjammable” quantum gyroscopes designed for GPS-denied environments.

Quantum Error Correction: A patented, AI-driven, code-agnostic universal decoder developed by Prof. Lior Wolf (Tel Aviv University), which aims to reduce computational overhead in noisy quantum processors. Quantum Algorithms: Specialized subsidiaries, including CliniQuantum, are focused on quantum-enhanced Markov Chain Monte Carlo methods for drug discovery and logistics. The transaction involved issuing common stock and pre-funded warrants representing approximately 40% of Viewbix’s capital stock, with further performance-based milestones that could trigger the issuance of an additional 12.7 million shares. Alongside the closing, Viewbix raised $1.4 million in a private placement to fund general working capital and the commercialization of its newly acquired quantum IP. This move effectively serves as a “reverse-merger” entry for an Israeli quantum startup ecosystem into the Nasdaq. While Viewbix’s legacy digital media and grammar-correction segments remain, the company’s future valuation is now heavily tied to its ability to operationalize Quantum X Labs’ “Atoms.” The team is led by Prof. Nir Sharon (Tel Aviv University) and maintains strong academic ties to the Weizmann Institute, positioning the company to compete in the high-precision sensing and error-correction niches of the global quantum market. For further financial and corporate details regarding the acquisition and private placement, consult the official announcement via GlobeNewswire here. March 4, 2026 Mohamed Abdel-Kareem2026-03-04T16:13:08-08:00 Leave A Comment Cancel replyComment Type in the text displayed above Δ This site uses Akismet to reduce spam. Learn how your comment data is processed.

Read Original

Tags

drug-discovery
quantum-finance
quantum-optimization
quantum-sensing
quantum-investment
quantum-commercialization
quantum-algorithms
quantum-hardware
quantum-error-correction
startup

Source Information

Source: Quantum Computing Report